Tech Company Financing Transactions
Ablynx Funding Round
Ablynx, operating out of Ghent/Zwijnaarde, raised $50 million from KBC Securities, Abingworth and Alta Partners.
Transaction Overview
Company Name
Announced On
8/23/2006
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series C
Investors
KBC Securities (Lead Investor) (Ruth Devenyns)
Proceeds Purpose
Ablynx will now be able to fund operations through to at least mid-2008, allowing the Company to further develop its product pipeline based on its proprietary Nanobody technology and to rapidly increase its headcount which is currently just over seventy.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
Technologiepark 21
Ghent/Zwijnaarde, 9052
Belgium
Ghent/Zwijnaarde, 9052
Belgium
Phone
Website
Email Address
Overview
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies for a range of serious human diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Edwin Moses
Chief Financial Officer
Wim Ottevaere
Chief Medical Officer
Robert Zeldin
Chief Scientific Officer
Antonin de Fougerolles
VP - Human Resources
Guido Gielen
Browse more venture capital transactions:
Prev: 8/23/2006: Arcxis Biotechnologies venture capital transaction
Next: 8/24/2006: ChemoCentryx venture capital transaction
Share this article
News on VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs